跳至主要内容
临床试验/NCT01802203
NCT01802203已完成不适用

trūFreeze® Spray Cryotherapy Patient Registry

US Endoscopy Group Inc.16 个研究点 分布在 1 个国家目标入组 275 人开始时间: 2013年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
275
试验地点
16
主要终点
Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

研究概览

简要总结

To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

详细描述

This is a prospective, multi-center registry of patients who are currently undergoing spray cryotherapy using the trūFreeze® device. The registry population consists of patients who are being treated using the spray cryotherapy trūFreeze® device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.

Patients eligible to participate in the registry will have disease and treatment specific data collected throughout therapy and long-term follow-up. Subjects will be considered to have completed the registry when data from the 5 year follow-up visit has been collected. The beginning of the follow-up period commences with the first endoscopic treatment session.

Subjects may be withdrawn prior to this for any of the following reasons:

  1. Death, or
  2. Lost to Follow-Up, or
  3. Withdrawal of consent, or
  4. Discontinuation by the investigator. Three attempts at contact using two different methods are required prior to determination that the subject is lost to follow-up. Attempts at contact must be with certified letters OR documented telephone contact.

The registry will utilize electronic case report forms using a web-based platform housed at the University of North Carolina at Chapel Hill. Access to the database will be limited to individuals involved in the research registry and will require a unique user ID and password. All access to the database and web-based application will be encrypted (HTTPS) and electronic systems compliant with applicable privacy and security regulations. To maintain patient confidentiality, all subjects will be assigned a registry identification number, and this will be the only link between subject identity and treatment information. Read-only access will be provided to any personnel who is not an administrator or responsible for data entry.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • GI conditions include:
  • Barrett's Esophagus (BE) with or without dysplasia
  • Squamous dysplasia
  • Esophageal cancer, any stage
  • Pulmonary conditions include:
  • Any endobronchial cancerous or precancerous disease located within the central airways
  • Any non-malignant endobronchial process of the central airways that results in abnormal mucosa (i.e. granulation tissue, papillomatosis, sarcoidosis, tuberculosis, etc.)
  • Tracheal or bronchial stenosis (malignant or benign)
  • Any pleural disease, malignant or benign All subjects are required to be able to provide written informed consent

排除标准

  • Gastrointestinal Exclusion Criteria
  • Contraindication to spray cryotherapy.
  • Prior treatment with spray cryotherapy. Previous or concurrent treatment using other mucosal therapies such as endoscopic mucosal resection or radiofrequency ablation is acceptable.
  • Below 18 years of age
  • Pulmonary Exclusion Criteria
  • Contraindication to spray cryotherapy.
  • Prior treatment with spray cryotherapy. Previous or concurrent treatment using other mucosal therapies is acceptable.
  • Tracheoesophageal fistula.
  • Bronchopleural fistula.
  • Current untreated pneumothorax.
  • Clinically significant hypoxia refractory to supplemental oxygen therapy.
  • Below 18 years of age

结局指标

主要结局

Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

时间窗: 5 years

The registry population consists of patients who are being treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.

次要结局

  • Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.(5 years)

研究者

发起方
US Endoscopy Group Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验